Yiqing Huang1, Dapeng Zhang1, Zihan Li2, Gang Cheng1,*
1Oncology Department, The Affiliated Bozhou Hospital of Anhui Medical University, Bozhou 236800, Anhui, China.
2Cardiovascular Medicine, The Affiliated Bozhou Hospital of Anhui Medical University, Bozhou 236800, Anhui, China.
*Corresponding author: Gang Cheng
Abstract
Objective: To analyze the efficacy of camrelizumab combined with lenvatinib in patients with advanced liver cancer and its effects on T lymphocyte subsets. Methods: A total of 80 patients with advanced liver cancer who received treatment in our hospital from January 2023 to December 2025 were selected for retrospective analysis. Forty patients in the control group received lenvatinib treatment, while 40 patients in the observation group received camrelizumab combined with lenvatinib. The clinical efficacy and improvement in T lymphocyte subsets were compared between the two groups. Results: After treatment, the objective response rate in the observation group was significantly higher than that in the control group (P < 0.05). The percentages of CD3+ and CD4+ T cells and the CD4+/CD8+ ratio in the observation group were higher than those in the control group, while the percentage of CD8+ T cells was lower than that in the control group (P < 0.05). Conclusion: Camrelizumab combined with lenvatinib shows significant therapeutic effects in patients with advanced liver cancer and can effectively improve T lymphocyte subsets.
References
[1] Zheng W, Wei P. Effects of camrelizumab combined with lenvatinib on the efficacy and T lymphocyte subsets in patients with advanced liver cancer. Chin J Drug Appl Monit. 2024;21(4):381-4.
[2] Zhang Y. Efficacy of lenvatinib combined with camrelizumab in the treatment of advanced liver cancer and its effects on tumor markers. Clin Ration Drug Use. 2025;18(32):95-7.
[3] Huang QL. Effect of camrelizumab combined with lenvatinib in the treatment of advanced unresectable liver cancer. Shenzhen J Integr Tradit Chin West Med. 2025;35(19):105-7,111.
[4] Zhao YG, Li A, Zhang Q, et al. Effects of RALOX-HAIC combined with camrelizumab and lenvatinib in advanced liver cancer and its influence on serum tumor-related indicators and recurrence rate. Clin Misdiagn Misther. 2025;38(11):61-6.
[5] Zhang LL. Analysis of the efficacy of camrelizumab, lenvatinib combined with the FOLFOX4 regimen in the treatment of advanced liver cancer. Traffic Med. 2025;39(1):40-3.
[6] Qiu LB, Chen QZ, Lian HN, et al. Comparison of the short-term efficacy of HAIC and TACE combined with camrelizumab and lenvatinib in patients with advanced primary liver cancer. Med Theory Pract. 2025;38(20):3495-8.
[7] Huang Y, Yang ZY, Luo M. Analysis of the efficacy and safety of camrelizumab combined with lenvatinib in patients with advanced primary liver cancer. J Pract Hepatol. 2024;27(4):595-8.
[8] Li YY, Luo JJ, Li W, et al. Observation on the efficacy of camrelizumab combined with lenvatinib in the treatment of advanced liver cancer. Chin J Health Care Med. 2024;26(5):702-4.
[9] Chen JH, Guo RF, Lan KT, et al. Analysis of the efficacy and safety of camrelizumab combined with lenvatinib in patients with advanced liver cancer after local treatment. China Prescr Drug. 2024;22(8):122-5.
[10] Yang C. Clinical efficacy and safety of camrelizumab combined with lenvatinib in the treatment of advanced liver cancer. Clin Ration Drug Use. 2024;17(26):92-4.
How to cite this paper
Analysis of the Efficacy of Camrelizumab Combined with Lenvatinib in Patients with Advanced Liver Cancer and Its Effects on T Lymphocyte Subsets
How to cite this paper: Yiqing Huang, Dapeng Zhang, Zihan Li, Gang Cheng. (2026) Analysis of the Efficacy of Camrelizumab Combined with Lenvatinib in Patients with Advanced Liver Cancer and Its Effects on T Lymphocyte Subsets. International Journal of Clinical and Experimental Medicine Research, 10(2), 119-122.
DOI: http://dx.doi.org/10.26855/ijcemr.2026.03.011